Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II TrialChunyan Lan, Xin Huang, Jiayu Ling et al.|Journal of Clinical Oncology|2020Cited by 217
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancerWei Wei, Xiaohua Ban, Fan Yang et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 38
A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD scoreFan Yang, Jundong Li, Wei Wei et al.|Frontiers in Genetics|2023Cited by 3
Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.Wei Wei, Min Zheng, Xiaohua Ban et al.|Journal of Clinical Oncology|2021Cited by 2